Phase II/III Trial of Bone Marrow-derived Mesenchymal Stem Cell Transplantation in Chronic Spinal Cord Injury
Spinal Cord Injury
Enrolment: 20 · Results not recorded
Loading the evidence…
Biologic · Rodent cell preparation with a BrdU tracking label; no ChEMBL entity queried as no defined chemical entity exists. CLASS-LEVEL and MODALITY-LEVEL trial match: recorded trials are human autologous bone marrow-derived MSC studies in spinal cord injury, an exact injury indication, but no trial uses passage-15 or BrdU-labelled cells. Note NCT02237547 is WITHDRAWN at 0 enrolment, NCT01676441 TERMINATED and NCT01162915 SUSPENDED.
6 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Spinal Cord Injury
Enrolment: 20 · Results not recorded
Spinal Cord Injuries
Enrolment: 14 · Results not recorded
Spinal Cord Injury
Enrolment: 0 · Results not recorded
Spinal Cord Injury
Enrolment: 20 · Results not recorded
Spinal Cord Injury
Enrolment: 10 · Results not recorded
Spinal Cord Injuries
Enrolment: 20 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Partial sciatic nerve ligation (one-third to one-half of the right sciatic nerve trunk tightly ligated with 6-0 suture above the peroneal/tibial bifurcation), performed 9 days after intrathecal catheterisation
Repetitive intrathecal mesenchymal stem cell delivery did not alter partial sciatic nerve ligation-induced mechanical allodynia or thermal hyperalgesia over 20 days. Iba1 immunostaining in the ipsilateral dorsal horn was increased by ligation and only non-significantly reduced by the cells (94 per…
Extraction: extract · Supplied extraction confidence: 0.94. Machine-extracted fields require source verification.